Advisor Partners LLC United Therapeutics Corp Transaction History

Advisor Partners LLC

  • $1.42 Billion
  • Q2 2022

A detailed history of Advisor Partners LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Advisor Partners LLC holds 1,369 shares of UTHR stock, worth $510,486. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,369
Previous 1,259 8.74%
Holding current value
$510,486
Previous $226,000 42.92%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022
BUY
$174.81 - $241.14 $19,229 - $26,525
110 Added 8.74%
1,369 $323,000
Q1 2022

Apr 27, 2022
BUY
$166.16 - $213.96 $1,661 - $2,139
10 Added 0.8%
1,259 $226,000
Q4 2021

Feb 04, 2022
BUY
$184.32 - $216.08 $9,768 - $11,452
53 Added 4.43%
1,249 $270,000
Q3 2021

Nov 15, 2021
SELL
$179.86 - $214.88 $20,324 - $24,281
-113 Reduced 8.63%
1,196 $221,000
Q2 2021

Aug 12, 2021
BUY
$170.47 - $211.93 $4,261 - $5,298
25 Added 1.95%
1,309 $235,000
Q1 2021

Jun 01, 2021
SELL
$153.94 - $174.85 $5,233 - $5,944
-34 Reduced 2.58%
1,284 $215,000
Q4 2020

Feb 17, 2021
BUY
$101.87 - $151.79 $134,264 - $200,059
1,318 New
1,318 $200,000
Q4 2018

Jan 29, 2019
SELL
$101.4 - $128.73 $159,502 - $202,492
-1,573 Closed
0 $0
Q3 2018

Nov 06, 2018
BUY
$113.81 - $129.46 $179,023 - $203,640
1,573 New
1,573 $201,000
Q1 2018

May 03, 2018
SELL
$107.21 - $151.94 $196,837 - $278,961
-1,836 Closed
0 $0
Q4 2017

Jan 26, 2018
BUY
$118.58 - $151.28 $2,015 - $2,571
17 Added 0.93%
1,836 $256,000
Q3 2017

Nov 03, 2017
BUY
$114.6 - $136.81 $208,457 - $248,857
1,819
1,819 $213,000

Others Institutions Holding UTHR

# of Institutions
669
Shares Held
42.8M
Call Options Held
194K
Put Options Held
295K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Advisor Partners LLC Portfolio

Follow Advisor Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisor Partners LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email